Loading...
XHKG1345
Market cap369mUSD
Jan 07, Last price  
2.33HKD
1Q
9.39%
Jan 2017
-16.79%
IPO
-41.01%
Name

Shanghai Pioneer Holding Ltd

Chart & Performance

D1W1MN
XHKG:1345 chart
P/E
18.57
P/S
1.73
EPS
0.12
Div Yield, %
2.70%
Shrs. gr., 5y
-1.17%
Rev. gr., 5y
-0.72%
Revenues
1.57b
+0.68%
570,647,000717,831,000958,723,0001,272,247,0001,540,398,0001,460,899,0001,790,275,0002,153,935,0001,624,305,0001,315,978,0001,332,037,0001,434,820,0001,556,040,0001,566,673,000
Net income
146m
-38.07%
70,435,00095,675,000186,369,000238,372,000261,718,000174,302,000237,445,000278,925,00084,597,000104,627,00052,448,000142,633,000235,296,000145,718,000
CFO
-119m
L
71,205,000-21,777,000120,758,00047,937,000-17,778,000304,690,000342,039,000233,628,000128,667,000280,642,00074,239,000242,064,00093,295,000-118,686,000
Dividend
Oct 30, 20240.048 HKD/sh
Earnings
May 23, 2025

Profile

China Pioneer Pharma Holdings Limited, an investment holding company, markets, promotes, and sells pharmaceutical products and medical devices primarily in the People's Republic of China. It has a portfolio of pharmaceutical products, such as ophthalmology, pain management, cardiovascular, immunology, gynecology, gastroenterology, and other therapeutic areas, as well as medical devices, including ophthalmology, orthopedics, odontology, and wound care products. The company sells its products to hospitals and medical institutions, and pharmacies. It also sells ancillary tools and leases accessories; and sells dental devices. In addition, the company engages in the sale of imported in-licensed prescription products. China Pioneer Pharma Holdings Limited was founded in 1996 and is headquartered in Shanghai, the People's Republic of China. China Pioneer Pharma Holdings Limited is a subsidiary of Pioneer Pharma (BVI) Co., Ltd.
URL
http://www.pioneer-pharma.com/
IPO date
Nov 05, 2013
Employees
361
Domiciled in
CN
Incorporated in
KY

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
1,566,673
0.68%
1,556,040
8.45%
Cost of revenue
1,433,144
1,325,400
Unusual Expense (Income)
NOPBT
133,529
230,640
NOPBT Margin
8.52%
14.82%
Operating Taxes
51,451
64,547
Tax Rate
38.53%
27.99%
NOPAT
82,078
166,093
Net income
145,718
-38.07%
235,296
64.97%
Dividends
(77,503)
(84,656)
Dividend yield
3.59%
3.19%
Proceeds from repurchase of equity
(22,727)
1,092
BB yield
1.05%
-0.04%
Debt
Debt current
61,272
29,586
Long-term debt
26,797
16,745
Deferred revenue
41,420
43,600
Other long-term liabilities
Net debt
(153,496)
(398,834)
Cash flow
Cash from operating activities
(118,686)
93,295
CAPEX
(30,922)
(74,270)
Cash from investing activities
69,507
(12,993)
Cash from financing activities
(50,562)
(91,025)
FCF
(84,997)
12,043
Balance
Cash
124,427
289,008
Long term investments
117,138
156,157
Excess cash
163,231
367,363
Stockholders' equity
723,603
686,929
Invested Capital
969,976
696,535
ROIC
9.85%
27.06%
ROCE
11.62%
21.19%
EV
Common stock shares outstanding
1,178,462
1,190,884
Price
1.83
-17.94%
2.23
33.53%
Market cap
2,156,585
-18.79%
2,655,672
32.19%
EV
2,014,413
2,355,590
EBITDA
152,479
244,272
EV/EBITDA
13.21
9.64
Interest
2,478
1,713
Interest/NOPBT
1.86%
0.74%